“Biomarkers in the diagnosis and treatment of myasthenia”- Dra Eugenia Martínez
The discovery of antibodies against proteins of the neuromuscular junction has helped to understand the physiopathology of myasthenia and to define subgroups of patients with a common clinical phenotype. In this work, we studied if beyond of its diagnostic utility, the presence of antibodies has implications in the treatment response. We analyzed the clinical and immunologic long-term outcome of patients with drug-resistant myasthenia treated with rituximab, and compared the response observed between AChR+ myasthenia and MuSK+ myasthenia. Moreover, we investigated the presence of new autoantibodies in patients with seronegative myasthenia, those with non-detectable AChR or MusK antibodies.
Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, Suárez-Calvet X, Muñoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juárez C, Verschuuren JJ, Illa I.
Neurology. 2012 Jan 17;78(3):189-93.
Dr. Eugenia Martinez-Hernandez studied Medicine at the University of Murcia, Spain. She completed an internship in Internal Medicine followed by training in Neurology at Hospital de la Santa Creu i Sant Pau, Barcelona. At Sant Pau, she then was a clinical and research fellow in Neuromuscular Disorders (2009-2012). During her doctoral studies Dr. Martinez-Hernandez spent 1 year at the University of Pennsylvania where she pursued additional training in molecular mechanisms underlying autoimmune nervous system diseases. Her doctoral thesis on novel biomarkers in myasthenia gravis, under the direction of Dr. Isabel Illa, has been awarded cum laude. She has on-going collaborations with the Departments of Neurology at Leiden University, the Netherlands, and Mayo Clinic, USA. In 2013 she was awarded a Río-Hortega grant and is currently working at IDIBAPS and Hospital Clinic as a clinical neurologist and post-doctoral fellow in Neuroimmunology with Drs. Dalmau, Graus and Saiz.
Place: CELLEX sala A11